EGD PATIENT SELECTION

WITH PROBE-BASED CONFOCAL LASER ENDOMICROSCOPY (pCLE)

Patients who would most benefit from a pCLE procedure using Cellvizio[®], the real-time in vivo cellular imaging platform

INDICATION	RECOMMENDED PROFILE	CELLVIZIO [®] CLINICAL VALUE
SEVERE OR CHRONIC GERD / ACID REFLUX	 Severe or chronic GERD Heartburn, nocturnal pain Family history of Barrett's or Esophageal CA Males, especially white males over 50^{1,2} 	 ~10% of people with chronic GERD symptoms develop Barrett's³ Patients can have Barrett's without visible columnar lined epithelium⁴ 25% of EAC is missed at index endoscopy⁶ 2x more Barrett's detected with Cellvizio vs. conventional biopsy^{4,5}
BARRETT'S ESOPHAGUS SURVEILLANCE	 Patients with suspected Barrett's⁴ Patients diagnosed with Barrett's⁴ 	 Enables targeted biopsies of suspected mucosal abnormalities, increasing diagnostic yield and limiting random biopsies⁷ Rule-in or rule-out Intestinal Metaplasia⁸ 2x detection of dysplasia in Barrett's with fewer biopsies⁹ Orient immediate endoscopic therapy^{9,10}
DYSPLASIA TREATMENT	 Patients diagnosed with Barrett's¹¹ Patients undergoing endoscopic eradication therapy¹⁴ 	 Follow up during dysplasia treatment - check before ablation treatment¹² Define location and lateral extent of neoplasia inducing clinical intervention¹³ RFA and ESD margin assessment - check after ablation treatment¹⁴
GASTRIC INTESTINAL METAPLASIA (GIM)	 East Asian descent¹⁵ Patients undergoing surveillance of known GIM¹⁶ 	 GIM increases the risk of Gastric Cancer by 6-fold¹⁶ 92% sensitivity, 97% specificity¹⁷ Nearly 2x diagnostic yield, enabling reliable diagnosis¹⁷
GASTRIC CANCER SCREENING	 East Asian descent¹⁸ Family history of stomach cancer¹⁸ Diagnosis of GIM or atrophic gastritis²¹ Suspected neoplasms²¹ 	 Early detection of gastric cancer and precancerous gastric lesions is essential for each GI endoscopy¹⁹ 94–96% accuracy in diagnosis of malignancy in early gastric cancer vs. conventional biopsies²⁰
COMPLICATION DUE TO BIOPSY	 Older patients Risky patients (e.g.: taking blood thinners)²² 	 Esophagus: 58% of biopsies could be avoided¹⁰ Stomach: 68% fewer biopsies with Cellvizio¹⁷ Detect real-time, and avoid complications with biopsies¹⁷





BIBLIOGRAPHY

BARRETT'S ESOPHAGUS

- 1. Gerson L.B. et al. Use of a simple symptom questionnaire to predict BE in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol, 2001.
- 2. Butt J. et al. Barrett esophagus: when to endoscope. Clinical Endoscopy, 2014.
- Web MD Medical Reference, Barrett's Esophagus: Symptoms, Causes and Treatments, Accessed Sep 2017, https://www.webmd.com/heartburn-gerd/ qa/what-is-barretts-esophagus.
- 4. Richardson C. et al. Real-time diagnosis of Barrett's esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users, Surgical Endoscopy, 2019.
- Burnette J. et al. Utility of probe-Based Confocal Laser Endomicroscopy in screening work-up for Barrett's esophagus. Abstract at SAGES 2015.
- 6. Visrodia K. et al. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology, 2016.
- 7. Al-Mansour M.R. et al. SAGES TAVAC safety and efficacy analysis confocal laser endomicroscopy. Surg Endosc, 2020.
- 8. Kiesslich R. et al. In vivo histology of Barrett's Esophagus and Associated Neoplasia by CLE, Clinical Gastro and Hepatology, 2006.
- Sharma P. et al. Real-time Increased Detection of Neoplastic Tissue in Barrett's Esophagus with probe- based Confocal Laser Endomicroscopy: Final Results of a Multi-center Prospective International Randomized Controlled Trial. Gastrointestinal Endoscopy, 2011.
- Bertani H. et al. Improved. Detection of Incident Dysplasia by Probe-Based Confocal Laser Endomicroscopy in a Barrett's Esophagus Surveillance Program Digestive Diseases and Sciences, 2013.

- 11. Canto M.I. et al. In vivo endoscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial. Gastrointestinal Endoscopy, 2013.
- 12. Caillol F. et al. Probe confocal laser endomicroscopy in the therapeutic endoscopic management of Barrett's dysplasia. Ann Gastroenterol, 2017.
- Wang K. et al. Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. UEGW Journal, 2015.
- 14. Konda V.J. et al. Confocal laser endomicroscopy: potential in the management of Barrett's esophagus. Dis Esophagus, 2010.

GASTRIC DISEASE

- Jencks D.S. et al. Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer. Gastroenterol Hepatol (N Y), 2018.
- **16.** Zullo A. et al. Follow-up of intestinal metaplasia in the stomach: When, how and why. World J Gastrointest Oncol, 2012.
- Li Zhen et al. Confocal laser endomicroscopy for in vivo detection of gastric intestinal metaplasia: a randomized controlled trial, Endoscopy, 2013
- **18.** Sitarz R. et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res, 2018.
- **19.** Li Z. et al. New Classification of Gastric Pit Patterns and Vessel Architecture Using Probebased Confocal Laser Endomicroscopy, J Clin Gastroenterol, 2015.
- 20. Wallace M. et al. Miami classification for pCLE. Endoscopy, 2011.
- **21.** Gomez J.M. et al. Gastric intestinal metaplasia and early gastric cancer in the west: a changing paradigm. Gastroenterol Hepatol, 2014.
- 22. Ahmed M. Blood thinners and gastrointestinal endoscopy. World J Gastrointest Endosc, 2016.

Cellvizio® IV.E. with Confocal Miniprobes™ are regulated Medical Device, CE marked (CE 0459) (Class IIa - NB : G-MED) and FDA cleared. Cellvizio® IV.E. with Confocal Miniprobes™ are confocal laser systems with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells and vessels and their organization or architecture. These statements and the associated reference to specific clinical studies, are not intended to represent claims of safety or effectiveness for detecting or treating any specific condition or disease state. Rather this information is intended to provide useful reference to specific clinical uses. Any diagnostic assessment should always be made by the attending physician, based on the evaluation of all sources of clinical, endoscopic and other relevant information. These statements have not been reviewed, cleared, or approved by the U.S. FDA. The use of this medical device is exclusively reserved for healthcare professionals.